Send to:

Choose Destination
See comment in PubMed Commons below
Biomaterials. 2013 May;34(16):4002-12. doi: 10.1016/j.biomaterials.2013.02.026. Epub 2013 Feb 28.

Treatment of diabetes mellitus with microencapsulated fetal human liver (FH-B-TPN) engineered cells.

Author information

  • 1Laboratory for the Study and Transplant of Pancreatic Islets (LSTPI), Department of Internal Medicine, University of Perugia, Via Enrico dal Pozzo, s.n.c., Perugia 06126, Italy.


Transplantation of whole human pancreases or isolated islets into patients with type 1 diabetes mellitus has been severely hampered by the scarcity of cadaveric human donor organs, which mandates search for insulin producing cells/tissue source alternatives. Recent progress in stem cell biology has started looking into functionally competent, insulin-secreting progenitor cells. It had been previously observed that induced expression of the β-cell transcriptional factor of the pancreatic and duodenal homeobox gene1 (PDX1), in human hepatocytes, may activate multiple features of the β-cell phenotype. These "FH-B-TPN" cells were shown to release insulin in response to physiological glucose stimulation both, in vitro and in vivo. However, because FH-B-TPNs lack the expression of a number of β-cell or non β-cell genes, and are associated with low insulin content, we aimed to determine whether these cells, upon physical manipulation and envelopment within "clinical grade" alginate-based microcapsules, would reverse hyperglycemia after graft into diabetic animal models.

Copyright © 2013 Elsevier Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk